TriangleNCT00396383 · OUTCOME
Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- Day 1 up to day 4
What was measured
Number of participants achieving a target of ≥ 4\*10\^6 CD34+ cells/kg during apheresis for up to 4 consecutive days. Apheresis was performed six hours following treatment with plerixafor 240 µg/kg (alone). Target was calculated as the sum of all daily values collected from central laboratory data over up to 4 apheresis days.
Analysis population: All participants who received plerixafor
Groups in this outcome
Participants With Multiple Myeloma (MM)
Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.
| Group | Source count |
|---|---|
| Participants With Multiple Myeloma (MM) | 9 |
Reported measurements
Participants Who Achieved ≥4*10^6 cells
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Participants With Multiple Myeloma (MM) | 4 | Not reported | Not reported | Not reported | Not reported |
Participants Who Achieved <4*10^6 cells
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Participants With Multiple Myeloma (MM) | 5 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 4
- title
- Participants Who Achieved ≥4*10^6 cells
- categories
- measurements
- group Id
- OG000
- value
- 5
- title
- Participants Who Achieved <4*10^6 cells
- denoms
- counts
- group Id
- OG000
- value
- 9
- units
- Participants
- description
- Number of participants achieving a target of ≥ 4\*10\^6 CD34+ cells/kg during apheresis for up to 4 consecutive days. Apheresis was performed six hours following treatment with plerixafor 240 µg/kg (alone). Target was calculated as the sum of all daily values collected from central laboratory data over up to 4 apheresis days.
- groups
- description
- Participants with MM who were eligible for autologous peripheral blood stem cell transplantation were given 240 µg/kg daily subcutaneous plerixafor for up to 4 days.
- id
- OG000
- title
- Participants With Multiple Myeloma (MM)
- param Type
- NUMBER
- population Description
- All participants who received plerixafor
- reporting Status
- POSTED
- time Frame
- Day 1 up to day 4
- title
- Number of Participants Who Achieved ≥4*10^6 CD34+ Cells/kg
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice